Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 4, 2024, at 7:00 a.m. Eastern Time.
This event presents an opportunity for investors and interested parties to gain insights into Nautilus's innovative proteomics platform. A live and archived webcast of the presentation will be accessible through the 'Investors' section of the company's website at www.nautilus.bio, allowing for widespread access to the discussion.
Nautilus Biotechnology (NASDAQ: NAUT), pioniere nell'analisi del proteoma a singola molecola, ha annunciato la sua partecipazione alla 22ª Conferenza Globale Annuale sulla Salute di Morgan Stanley a New York. La direzione dell'azienda parteciperà a una discussione informale il 4 settembre 2024, alle 7:00 ora orientale.
Questo evento rappresenta un'opportunità per investitori e parti interessate di ottenere informazioni sulla piattaforma innovativa di proteomica di Nautilus. Un webcast dal vivo e registrato della presentazione sarà accessibile attraverso la sezione 'Investitori' del sito web dell'azienda all'indirizzo www.nautilus.bio, permettendo un accesso diffuso alla discussione.
Nautilus Biotechnology (NASDAQ: NAUT), pionero en el análisis del proteoma de molécula única, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley en Nueva York. La dirección de la empresa participará en un chat junto a la chimenea el 4 de septiembre de 2024, a las 7:00 a.m. hora del Este.
Este evento representa una oportunidad para que inversionistas y partes interesadas obtengan información sobre la innovadora plataforma de proteómica de Nautilus. Un webcast en vivo y grabado de la presentación estará disponible a través de la sección 'Inversores' del sitio web de la empresa en www.nautilus.bio, lo que permitirá un acceso amplio a la discusión.
나우틸러스 바이오테크놀로지(NASDAQ: NAUT)는 단일 분자 프로테옴 분석의 선구자로서 뉴욕에서 열리는 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 임원들은 2024년 9월 4일 오전 7시(동부 표준시)에 파이어사이드 채팅에 참여할 예정입니다.
이 행사는 투자자와 관심 있는 관계자들이 나우틸러스의 혁신적인 프로테오믹스 플랫폼에 대한 통찰력을 얻을 수 있는 기회를 제공합니다. 발표의 실시간 및 녹화된 웹캐스트는 회사 웹사이트의 '투자자' 섹션인 www.nautilus.bio를 통해 접근 가능하여 광범위한 논의 접근이 가능합니다.
Nautilus Biotechnology (NASDAQ: NAUT), un pionnier dans l'analyse du protéome à molécule unique, a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley à New York. La direction de l'entreprise participera à un échange informel le 4 septembre 2024, à 7h00, heure de l'Est.
Cet événement offre une opportunité aux investisseurs et aux parties intéressées d'obtenir des informations sur la plateforme innovante de protéomique de Nautilus. Un webinaire en direct et enregistré de la présentation sera accessible via la section 'Investisseurs' du site web de l'entreprise à l'adresse www.nautilus.bio, permettant ainsi un accès large à la discussion.
Nautilus Biotechnology (NASDAQ: NAUT), ein Pionier in der Einzelmolekül-Proteomanalyse, hat seine Teilnahme an der 22. jährlichen Global Healthcare Conference von Morgan Stanley in New York angekündigt. Das Management des Unternehmens wird am 4. September 2024 um 7:00 Uhr Eastern Time an einem Fireside Chat teilnehmen.
Diese Veranstaltung bietet Investoren und Interessierten die Möglichkeit, Einblicke in die innovative Proteomics-Plattform von Nautilus zu gewinnen. Ein live und archiviertes Webcast der Präsentation wird über den Bereich 'Investoren' auf der Unternehmenswebsite unter www.nautilus.bio zugänglich sein, was einen breiten Zugang zur Diskussion ermöglicht.
- None.
- None.
SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.
Nautilus management is scheduled to participate in a fireside chat on Wednesday, September 4, 2024, at 7:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
FAQ
When is Nautilus Biotechnology (NAUT) participating in the Morgan Stanley Healthcare Conference?
Where can I watch the webcast of Nautilus Biotechnology's (NAUT) presentation at the Morgan Stanley conference?
What is Nautilus Biotechnology's (NAUT) main focus in biotechnology?
Is Nautilus Biotechnology (NAUT) a publicly traded company?
